CJC Peptide: What It Is, How It Works, and What the Evidence Says

A CJC peptide is a lab-made copy of growth hormone-releasing hormone (GHRH), the signal the pituitary gland uses to trigger growth hormone release. In everyday use, "CJC peptide" almost always refers to CJC-1295, a compound sold online as a research chemical rather than an approved medicine. This guide covers how it works, what small human trials found, how the DAC and DAC-free versions differ, and where U.S. regulators currently stand.

What Is a CJC Peptide?

CJC-1295 is a synthetic analog of GHRH developed in the 1990s to extend the natural hormone's very short action. The original compound attached a drug affinity complex (DAC) to the peptide so it would bind albumin in the blood and stay active for days instead of minutes.

Two versions dominate the market today:

• CJC-1295 with DAC — long-acting, with a reported half-life of roughly six to eight days.
• CJC-1295 without DAC — chemically closer to modified GRF(1-29), short-acting, with a half-life measured in minutes.

Confusingly, some vendors sell the DAC-free version under both names, so the label alone does not tell you what is in the vial. Some researchers spell the term "peptide cjc" or "CJC-1295 peptide," but these labels usually point to the same family of GHRH analogs.

How CJC-1295 Works in the Body

CJC-1295 binds to GHRH receptors on pituitary cells and prompts them to release growth hormone into the bloodstream. Higher growth hormone levels, in turn, raise insulin-like growth factor 1 (IGF-1), which is produced mainly in the liver.

Because the DAC version lingers in circulation, it produces a sustained rise in growth hormone and IGF-1 rather than the natural, pulse-like pattern the body normally uses. That difference matters: healthy growth hormone release is episodic, and constant elevation is not the same thing as a normal physiological rhythm.

A small 2006 study in healthy adults found that a single CJC-1295 injection raised growth hormone levels for up to six days. That trial was tiny, short, and never designed to measure muscle growth, fat loss, or any other performance outcome.

CJC-1295 With DAC vs. Without DAC

The two forms are compared directly because they behave very differently after injection.

Feature	CJC-1295 with DAC	CJC-1295 without DAC (Mod GRF 1-29)
Reported half-life	About 6–8 days	About 30 minutes
Growth hormone pattern	Continuous elevation	Short pulses
Common dosing claim	1–2 mg once or twice weekly	100 mcg, two to three times daily
FDA approval for human use	None	None
Anti-doping status	Banned by WADA	Banned by WADA

CJC-1295 is a peptide drug that falls under the FDA's rules for unapproved new drugs whenever it is marketed for human use. No version of it has been cleared for any medical indication.

What the Evidence Actually Shows

Human data on CJC-1295 is thin. The available studies are small, short, and focused on hormone levels rather than real-world outcomes.

• Growth hormone and IGF-1 do rise after injection in healthy adults.
• No controlled trial has shown that CJC-1295 builds muscle, burns fat, improves recovery, or slows aging.
• Long-term safety data in healthy people does not exist.

Marketing copy often stacks CJC-1295 with other compounds and lists benefits that were never measured in a clinical setting. Many researchers also look into bpc-157 peptide for inflammation alongside growth hormone peptides, although the two act through entirely different pathways and neither is FDA-approved for human use.

Elevated IGF-1 is a real safety concern. Chronically high IGF-1 has been associated with increased risk of certain cancers, which is one reason clinicians monitor IGF-1 closely when growth hormone therapy is prescribed.

Side Effects and Safety Concerns

Reported side effects from early studies and user accounts include injection-site reactions, flushing, headache, dizziness, and water retention. Because the drug is unregulated, the purity and actual contents of online vials are unknown.

Additional concerns include:

• Pituitary desensitization from continuous GHRH receptor stimulation
• Rising IGF-1 levels and the associated long-term cancer risk
• Changes in blood sugar and insulin sensitivity
• Allergic reactions to peptides or contaminants

Shoppers often ask are peptide supplements safe, and the honest answer is that safety depends entirely on the specific compound, dose, and source. Injectable research chemicals sold online carry far more risk than topical cosmetic peptides, so anyone considering this class of compound should talk with a physician who understands hormone therapy before injecting anything.

Legal Status in the United States

CJC-1295 is not FDA-approved for human use in the United States. It is not a scheduled controlled substance under federal law, but selling it as a drug for human consumption without approval is illegal.

In September 2023, the FDA placed CJC-1295 and several other peptides on its Category 2 list of bulk drug substances, which means compounding pharmacies operating under Section 503A may not use it in compounded preparations. Importing it for personal use is also restricted.

The World Anti-Doping Agency bans CJC-1295 at all times, in and out of competition, and most major sports organizations follow the same rule. Athletes who use it risk multi-year suspensions.

By contrast, most products sold as natural peptide supplements — collagen, creatine peptides, and similar ingredients — are dietary components, not injectables, and are regulated differently. Searches for best peptide supplements for women typically return collagen powders and skincare rather than GHRH analogs.

Bottom Line

CJC-1295 reliably raises growth hormone and IGF-1 in small short-term studies, but it has no approved medical use in the U.S. and no evidence base for the performance or anti-aging claims attached to it. Regulatory restrictions, uncertain product purity, and unresolved long-term safety questions all point the same direction: this is not a casual supplement.

COMMON QUESTIONS

Frequently Asked Questions

Is CJC-1295 legal in the US?

CJC-1295 is not FDA-approved for human use, so it cannot legally be sold as a drug or dietary supplement in the United States. It is not a federally scheduled controlled substance, but the FDA placed it on its Category 2 bulk substances list in 2023, which blocks compounding pharmacies from using it. Importing it for personal use is also restricted.

What does CJC-1295 actually do?

CJC-1295 mimics growth hormone-releasing hormone and stimulates the pituitary to release more growth hormone, which raises IGF-1 levels. Small short-term studies in healthy adults confirmed those hormone changes, but no controlled trial has shown muscle growth, fat loss, or anti-aging benefits from the peptide.

What is the difference between CJC-1295 with DAC and without DAC?

The DAC version binds albumin in the blood and stays active for roughly six to eight days, while the DAC-free version, often called Mod GRF(1-29), clears in about 30 minutes. That difference changes how often people inject and whether growth hormone rises continuously or in short pulses.